Vistagen Therapeutics, Inc. (VTGN)
0.3079
+0.01
(+3.32%)
USD |
NASDAQ |
Sep 30, 16:00
0.2952
-0.01
(-4.12%)
After-Hours: 20:00
Vistagen Therapeutics Enterprise Value : -17.72M for Sept. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 29, 2026 | -17.72M |
| September 28, 2026 | -17.77M |
| September 25, 2026 | -18.83M |
| September 24, 2026 | -17.85M |
| September 23, 2026 | -14.60M |
| September 22, 2026 | -19.79M |
| September 21, 2026 | -20.61M |
| September 18, 2026 | -20.30M |
| September 17, 2026 | -20.58M |
| September 16, 2026 | -20.71M |
| September 15, 2026 | -20.47M |
| September 14, 2026 | -20.15M |
| September 11, 2026 | -20.43M |
| September 10, 2026 | -20.34M |
| September 09, 2026 | -20.50M |
| September 08, 2026 | -20.14M |
| September 04, 2026 | -20.17M |
| September 03, 2026 | -20.02M |
| September 02, 2026 | -20.03M |
| September 01, 2026 | -20.15M |
| August 31, 2026 | -19.63M |
| August 28, 2026 | -19.72M |
| August 27, 2026 | -19.54M |
| August 26, 2026 | -19.41M |
| August 25, 2026 | -19.92M |
| Date | Value |
|---|---|
| August 24, 2026 | -20.13M |
| August 21, 2026 | -20.12M |
| August 20, 2026 | -20.25M |
| August 19, 2026 | -20.11M |
| August 18, 2026 | -20.21M |
| August 17, 2026 | -19.41M |
| August 14, 2026 | -19.07M |
| August 13, 2026 | -19.13M |
| August 12, 2026 | -19.35M |
| August 11, 2026 | -19.00M |
| August 10, 2026 | -19.24M |
| August 07, 2026 | -18.18M |
| August 06, 2026 | -18.35M |
| August 05, 2026 | -17.77M |
| August 04, 2026 | -17.63M |
| August 03, 2026 | -20.07M |
| July 31, 2026 | -20.25M |
| July 30, 2026 | -20.25M |
| July 29, 2026 | -20.15M |
| July 28, 2026 | -20.62M |
| July 27, 2026 | -20.73M |
| July 24, 2026 | -20.90M |
| July 23, 2026 | -20.92M |
| July 22, 2026 | -20.57M |
| July 21, 2026 | -20.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Onconetix, Inc. | -2.643M |
| ACADIA Pharmaceuticals, Inc. | 2.598B |
| Alnylam Pharmaceuticals, Inc. | 33.66B |
| Anika Therapeutics, Inc. | 253.76M |
| Savara, Inc. | 900.80M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.03M |
| Revenue (Quarterly) | 1.476M |
| Total Expenses (Quarterly) | 14.51M |
| EPS Diluted (Quarterly) | -0.3032 |
| Gross Profit Margin (Quarterly) | 86.65% |
| Profit Margin (Quarterly) | -882.8% |
| Earnings Yield | -553.7% |
| Normalized Earnings Yield | -553.59 |